| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1859 | |
| Phytochemical name or plant extracts | KTH-13-amine-monophenyl | |
| PMID | 26157554 | |
| Literature evidence | Previously, we identified several compounds with anti-cancer activity from the butanol fraction (Cb-BF) of Cordyceps bassiana. | |
| IUPAC name | 2-(1-phenylethyl)-4-(propan-2-yl)aniline | |
| Phytochemicals’ class or type of plant extracts | NA | |
| Source of phytochemicals or plant Extracts | Cordyceps bassiana | |
| Geographical availability | NA | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Cervical cancer | |
| Target gene or protein | Caspase 3, Caspase 9, Caspase-3, Caspase 8, Caspase 9, Bcl-2 | |
| Gene or Protein evidence | Furthermore, the levels of the active full-length forms of caspase-3 and caspase-9 were increased. In contrast, the levels of total forms of caspases-3, caspase-8, caspase-9, and Bcl-2 were decreased in KTH-13-AMP treated-cells. We also confirmed that the phosphorylation of STAT3, Src, and PI3K/p85, which is linked to cell survival, was diminished by treatment with KTH-13-AMP. | |
| Target pathways | We have demonstrated that KTH-13-AMP is able to suppress the cell viability of cancer cells through activation of apoptotic pathway. The apoptotic activity of this compound was induced by activation of pro-apoptotic signaling mediated via caspases and the Bcl family. The Src-PI3K-STAT3 signal, a representative anti-apoptotic signal cascade, is also suppressed by KTH-13-AMP treatment. | |
| IC50 | 135.1 mM against MDA-MB-231 | |
| Potency | Our results show that KTH-13-AMP possesses anti-cancer activity and has the potential to be used for cancer treatment. | |
| Cell line/ mice model | MDA-MB-231,HeLa ,C6 glioma | |
| Additional information | NA | |
| PubChem ID | 142727487 | |
| Additional PMIDs | NA | |
| Additional sources of information | NA | |
| Safety | NA |